Key facts
- This page summarizes Chris van Gorder's Form 4 filing for ABIOMED INC.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Dec 2022, 16:17.
Chris van Gorder - 22 Dec 2022 Form 4 Insider Report for ABIOMED INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 22 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Dec 2022, 16:17:28 UTC
- Prior SEC filing
- 12 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Dube (by power of attorney)
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chris van Gorder filed Form 4 for ABIOMED INC on 27 Dec 2022.
Change
- Previous filing in this sequence was filed on 12 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NASD
transaction
Common Stock, $.01 par value
Award
- Transaction value
- $0
- Shares
- +7,410
- Change %
- Price
- $0.000000*
- Shares after
- 0
- Date
- 22 Dec 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Chris van Gorder is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
Footnote F2
Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.